Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: Results from 3 years of prospectively registered data

Modern Rheumatology

Volumn 24, Issue 2, 2014, Pages 258-264

  Nakashima, Yasuharu ^a   Kondo, Masakazu ^b   Fukuda, Takaaki ^c   Harada, Hiroshi ^d   Horiuchi, Takahiko ^e   Ishinishi, Takashi ^f   Jojima, Hiroshi ^g   Kuroda, Koji ^h   Miyahara, Hisaaki ⁱ   Maekawa, Masayuki ^j   Nishizaka, Hiroaki ^k   Nagamine, Ryuji ^l   Nakashima, Hitoshi ^m   Otsuka, Takeshi ⁿ   Shono, Eisuke ^o   Suematsu, Eiichi ⁱ   Shimauchi, Takashi ^p   Tsuru, Tomomi ^q   Wada, Ken ^r   Yoshizawa, Shigeru ^s   Yoshizawa, Seiji ^t   Iwamoto, Yukihide ^a   more..

^a KYUSHU UNIVERSITY   (Japan)

^b Kondo Clinic of Rheumatology and Orthopaedic Surgery   (Japan)

^c KURUME UNIVERSITY MEDICAL CENTER   (Japan)

^d Morooka Orthopedic Clinic   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

^f Fukuseikai Hospital   (Japan)

^g Fukuoka University Chikushi Hospital   (Japan)

^h Kuroda Orthopedic Hospital   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^j Maekawa Orthopedics   (Japan)

^k KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

^l Sugioka Memorial Hospital   (Japan)

^m FUKUOKA UNIVERSITY   (Japan)

ⁿ Munakata Medical Association Hospital   (Japan)

^o Shono Rheumatology Clinic   (Japan)

^p Fukuoka Hoeikai Hospital   (Japan)

^q PS Clinic   (Japan)

^r Wada Orthopaedic Clinic   (Japan)

^s FUKUOKA NATIONAL HOSPITAL   (Japan)

^t HAMANOMACHI HOSPITAL   (Japan)

more..

Author keywords

Registry; Remission; Rheumatoid arthritis; Routine clinical practice; Tocilizumab

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; TOCILIZUMAB;

ADULT; ARTICLE; CLINICAL PRACTICE; DAS28; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG WITHDRAWAL; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; HYPERHIDROSIS; INFUSION RELATED REACTION; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; RHEUMATOID ARTHRITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84904057081     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.854069     Document Type: Article

References (25)

1. Nam JL , Winthrop KL , van Vollenhoven RF , Pavelka K , Valesini G , Hensor EM , et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying anti-rheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 2010 ; 69 : 976-86.
2. Smolen J S, Aletaha D , Bijlsma J W, Breedveld F C, Boumpas D , Burmester G , et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010 ; 69 : 631-7.
3. Schipper L G, Vermeer M , Kuper H H, Hoekstra M O, Haagsma C J, Den Broeder AA , et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis. 2012 ; 71 : 845-50.
4. Leffers HC , Ostergaard M , Glintborg B , Krogh NS , Foged H , Tarp U , et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis. 2011 ; 70 : 1216-22.
5. Burmester GR , Feist E , Kellner H , Braun J , Iking-Konert C , Rubbert-Roth A , et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis. 2011 ; 70 : 755-9.
6. Nishimoto N , Miyasaka N , Yamamoto K , Kawai S , Takeuchi T , Azuma J.Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009 ; 68 : 1580-4.
7. Smolen J S, Beaulieu A , Rubbert-Roth A , Ramos-Remus C , Rovensky J , Alecock E , et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008 ; 371 : 987-97.
8. Genovese MC , McKay JD , Nasonov EL , Mysler EF , de Silva NA , Alecock E , et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008 ; 58 : 2968-80.
9. Jones G , Sebba A , Gu J , Lowenstein M B, Calvo A , Gomez-Reino J J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010 ; 69 : 88-96.
10. Amery P , Keystone E , Tony H P, Cantagrel A , Van Vollenhoven R , Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomized placebo-controlled trial. Ann Rheum Dis. 2008 ; 67 : 1516-23.
11. Kremer JM , Blanco R , Brzosko M , Burgos-Vargas R , Halland AM , Vernon E , et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebocontrolled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011 ; 63 : 609-21.
12. Hetland M L, Christensen I J, Tarp U , Dreyer L , Hansen A , Hansen IT , et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010 ; 62 : 22-32.
13. Greenberg J D, Reed G , Decktor D , Harrold L , Furst D , Gibofsky A , Et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. A nn Rheum Dis. 2 012; 7 1: 1 134-42.
14. Takeuchi T , Tanaka Y , Amano K , Hoshi D , Nawata M , Nagasawa H , et al. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients - REACTION 52-week study. Rheumatology (Oxford). 2011 ; 50 : 1908-15.
15. Nakashima Y , Kondo M , Harada H , Horiuchi T , Ishinishi T , Jojima H , et al. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. Mod Rheumatol. 2010 ; 20 : 343-52.
16. Steinbrocker O , Traeger CH , Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAm Med Assoc. 1949 ; 25 : 659-62.
17. Felson DT , Smolen JS , Wells G , Zhang B , Tuyl LH , Funovits J , et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011 ; 70 : 404-13.
18. van Riel PL , van Gestel AM , van de Putte LB. Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers. Br J Rheumatol. 1996 ; 35 (Suppl 2) : 4-7.
19. Smolen J S, Aletaha D.Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum. 2011 ; 63 : 43-52.
20. Iking-Konert C , Aringer M , W ollenhaupt J , Mosch T , Tuerk S , Feist E , et al. Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria. Ann Rheum Dis. 2011 ; 70 : 1986-90.
21. Kawashiri S Y, Kawakami A , Iwamoto N , Fujikawa K , Aramaki T , Tamai M , et al. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index. Mod Rheumatol. 2011 ; 21 : 365-9.
22. Aletaha D , Funovits J , Keystone EC , Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum. 2007 ; 56 (10) : 3226-35.
23. Nishimoto N , Ito K , Takagi N.Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-Analysis of six initial trials and five long-term extensions. Mod Rheumatol. 2010 ; 20 : 222-32.
24. Sakai R , Tanaka M , Nanki T , Watanabe K , Yamazaki H , Koike R , et al. Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. Ann Rheum Dis. 2012 ; 71 : 1820-6.
25. Campbell L , Chen C , Bhagat S S, Parker R A, Ö s tö r A J.Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and metaanalysis of randomized controlled trials. Rheumatology (Oxford). 2011 ; 50 : 552-62.